FGFR1 and bladder transitional cell carcinoma: Experimental studies have confirmed that FGFR1 inhibits the proliferation, migration and invasion of T24 cells via activating the cGMP-PKG pathway, which provides a novel potential target for clinical diagnosis, treatment and prognosis of BLCA.